Method and kit for detecting target nucleic acid fragment

The CRISPR/Cas system forms a ternary complex to detect nucleic acid fragments without amplification, improving sensitivity and precision by using fluorescent signals in small reaction spaces.

JP7579577B2Active Publication Date: 2024-11-08THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH

Patent Information

Application Number
JP2021529209
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-04
Filing Date
2020-07-06
Publication Date
2024-11-08
Estimated Expiration
2040-07-06

AI Technical Summary

Technical Problem

Existing methods for detecting target nucleic acid fragments require amplification steps, limiting sensitivity and efficiency.

Method used

A method utilizing CRISPR/Cas family proteins to form a ternary complex with gRNA and target nucleic acid fragments, where a substrate nucleic acid fragment labeled with a fluorescent substance and quencher emits fluorescence upon cleavage, enabling detection without amplification in a reaction space of 10aL to 100pL.

Benefits of technology

Highly sensitive detection of target nucleic acid fragments is achieved without amplification, enhancing detection sensitivity and precision.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579577000003
    Figure 0007579577000003
  • Figure 0007579577000004
    Figure 0007579577000004
  • Figure 0007579577000005
    Figure 0007579577000005
Patent Text Reader

Abstract

A method for detecting a target nucleic acid fragment in a sample, said method comprising a step in which the sample is contacted with a gRNA, a Cas protein and a substrate nucleic acid fragment (wherein: the Cas protein expresses nuclease activity after forming a complex together with the gRNA and the target nucleic acid fragment; the substrate nucleic acid fragment is labeled with a fluorescent material and a fluorescence quenching material and, when the substrate nucleic acid fragment is cleaved by the nuclease activity, the fluorescent material is separated from the fluorescence quenching material and emits fluorescence by excitation light; and the contact is performed in a reaction space having a volume of 10 aL to 100 pL), and, when the target nucleic acid fragment exists in the sample, then the triple complex is formed and the substrate nucleic acid fragment is cleaved so that the fluorescent material is separated from the fluorescence quenching material, and a step in which the fluorescent material is irradiated with excitation light to detect the fluorescence. In this method, the detection of the fluorescence indicates that the target nucleic acid fragment exists in the sample.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method and a kit for detecting a target nucleic acid fragment. This application claims priority based on Japanese Patent Application No. 2019-125564 filed on July 4, 2019, the contents of which are incorporated herein by reference. [Background technology]

[0002] There is a demand for technology that can detect target nucleic acid fragments in samples with high sensitivity. For example, it is known that free DNA (cell-free DNA, cfDNA) released from cells due to cell death exists in blood. cfDNA from cancer patients also contains circulating tumor DNA (ctDNA), which is DNA derived from cancer cells.

[0003] There is also a demand for testing whether or not infectious disease-causing viruses are present in samples such as throat swabs and nasal swabs from subjects.

[0004] In addition, various cells secrete membrane vesicles called exosomes, and it is known that exosomes are contained in biological samples such as saliva, blood, urine, amniotic fluid, and malignant ascites, as well as in the supernatant of cultured cells. Exosomes contain various proteins, lipids, microRNA, DNA, etc. derived from the cells that secreted them.

[0005] In recent years, research has been conducted on detecting cfDNA and microRNA and DNA in membrane vesicles such as exosomes, and applying them to the early detection of cancer and various other diseases, prediction of the effectiveness of anticancer drugs, diagnosis of disease predisposition, diagnosis of genetic diseases, etc. Technology for detecting target nucleic acid fragments in a sample with high sensitivity can be applied to such fields, as an example.

[0006] Meanwhile, the adaptive immune mechanism discovered in prokaryotes is called the CRISPR / Cas system, and has been applied to genome editing in recent years. There are several families of CRISPR / Cas proteins. It has been revealed that among the CRISPR / Cas protein family, Cas12 and Cas13 form a ternary complex with crRNA and a target nucleic acid, and when the target nucleic acid is cleaved, they express an activity of cleaving the surrounding DNA or RNA. For example, Non-Patent Documents 1 to 3 report a method of detecting a target nucleic acid fragment with high sensitivity by utilizing such an activity of Cas12 and Cas13. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Gootenberg JS, et al., Nucleic acid detection with CRISPR-Cas13a / C2c2., Science, 356 (6336), 438-442, 2017. [Non-Patent Document 2] Gootenberg JS, et al., Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6., Science, 360 (6387), 439-444, 2018. [Non-Patent Document 3] Chen JS, et al., CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity., Science, 360 (6387), 436-439, 2018. Summary of the Invention [Problem to be solved by the invention]

[0008] However, the methods described in Non-Patent Documents 1 to 3 require a step of amplifying a target nucleic acid fragment. Therefore, an object of the present invention is to provide a technique capable of detecting a target nucleic acid fragment with high sensitivity without amplifying the target nucleic acid fragment. [Means for solving the problem]

[0009] The present invention includes the following aspects. [1] A method for detecting a target nucleic acid fragment in a sample, comprising the steps of: contacting the sample with a gRNA complementary to the target nucleic acid fragment, a CRISPR / Cas family protein, and a substrate nucleic acid fragment, wherein the CRISPR / Cas family protein expresses nuclease activity after forming a ternary complex with the gRNA and the target nucleic acid fragment; the substrate nucleic acid fragment is labeled with a fluorescent substance and a quencher; and when the substrate nucleic acid fragment is cleaved by the nuclease activity of the ternary complex and the fluorescent substance is separated from the quencher, it emits fluorescence when irradiated with excitation light; the contact is performed in a reaction space having a volume of 10 aL to 100 pL; and as a result, when the target nucleic acid fragment is present in the sample, the ternary complex is formed, the substrate nucleic acid fragment is cleaved, and the fluorescent substance is separated from the quencher; and irradiating the fluorescent substance with the excitation light and detecting the fluorescence, wherein the detection of the fluorescence indicates the presence of the target nucleic acid fragment in the sample. [2] The method according to [1], wherein the CRISPR / Cas family protein is a Cas12 protein or a Cas13 protein. [3] The method according to [1] or [2], wherein 0 or 1 target nucleic acid fragment is introduced per reaction space. [4] The method according to any one of [1] to [3], wherein the reaction space is a well formed on a substrate. [5] The method according to [4], wherein the CRISPR / Cas family protein is immobilized on the inner surface of the well. [6] A kit for detecting a target nucleic acid fragment, comprising: a substrate having wells with a volume of 10 aL to 100 pL formed on its surface; a gRNA complementary to a target nucleic acid fragment; a CRISPR / Cas family protein; and a substrate nucleic acid fragment, wherein the CRISPR / Cas family protein expresses nuclease activity after forming a ternary complex with the gRNA and the target nucleic acid fragment; the substrate nucleic acid fragment is labeled with a fluorescent substance and a quencher; and when cleaved by the nuclease activity of the ternary complex and the fluorescent substance is separated from the quencher, the substrate nucleic acid fragment emits fluorescence when irradiated with excitation light. [7] The kit described in [6], wherein the CRISPR / Cas family protein is a Cas12 protein or a Cas13 protein. [8] The kit described in [6] or [7], wherein the CRISPR / Cas family protein is fixed to the inner surface of the well. [9] The kit described in any one of [6] to [8], wherein the gRNA is immobilized on the inner surface of the well. Effect of the Invention

[0010] According to the present invention, a technique can be provided that enables highly sensitive detection of a target nucleic acid fragment without amplification. [Brief description of the drawings]

[0011] [Figure 1] 1(a) and (b) are schematic diagrams illustrating a method for detecting a target nucleic acid fragment. [Diagram 2] 1A is a top view showing an example of a fluidic device, and FIG. 1B is a cross-sectional view taken along line bb' in FIG. [Diagram 3] 1(a) to 1(c) are schematic cross-sectional views illustrating an example of a procedure for carrying out the method of the present embodiment. [Figure 4] 1(a) to 1(d) are schematic diagrams illustrating a method for immobilizing a CRISPR / Cas family protein on the inner surface of a well. [Diagram 5]1(a) to 1(f) are schematic cross-sectional views illustrating the steps of forming a well array. [Figure 6] 1(a) to 1(c) are typical fluorescent micrographs showing the results of Experimental Example 1. FIG. 1(d) is a graph showing the results of Experimental Example 1. [Figure 7] 6(a) to 6(c) are typical fluorescent micrographs showing the results of Experimental Example 2. FIG. 6(d) is a graph showing the results of Experimental Example 2. [Figure 8] 6(a) and 6(b) are graphs showing the results of Experimental Example 3. [Figure 9] 14(a) to (d) are representative fluorescence micrographs showing the results of Experimental Example 4. [Figure 10] 6(a) and 6(b) are graphs showing the results of Experimental Example 4. [Figure 11] 13 is a graph showing the results of Experimental Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Hereinafter, an embodiment of the present invention will be described in detail with reference to the drawings as needed. In the drawings, the same or corresponding parts are denoted by the same or corresponding reference numerals, and duplicate explanations will be omitted. In addition, the dimensional ratios in each drawing are exaggerated for the purpose of explanation, and do not necessarily correspond to the actual dimensional ratios.

[0013] [Method for detecting target nucleic acid fragments] In one embodiment, the present invention provides a method for detecting a target nucleic acid fragment in a sample, the method comprising the steps of contacting the sample with a gRNA complementary to the target nucleic acid fragment, a CRISPR / Cas family protein, and a substrate nucleic acid fragment, and irradiating the substrate nucleic acid fragment with excitation light and detecting fluorescence, wherein the detection of fluorescence indicates the presence of the target nucleic acid fragment in the sample.

[0014] In the method of this embodiment, the CRISPR / Cas family protein expresses nuclease activity after forming a ternary complex with the gRNA and the target nucleic acid fragment. The substrate nucleic acid fragment is labeled with a fluorescent substance and a quencher, and when it is cleaved by the nuclease activity of the ternary complex and the fluorescent substance is separated from the quencher, it emits fluorescence when irradiated with excitation light. The sample, gRNA, CRISPR / Cas family protein, and substrate nucleic acid fragment are contacted in a reaction space having a volume of 10 aL to 100 pL.

[0015] As a result, when a target nucleic acid fragment is present in a sample, the above-mentioned three-component complex is formed, the substrate nucleic acid fragment is cleaved, and the fluorescent substance is separated from the quencher. Then, when the excitation light is irradiated, the fluorescence is detected.

[0016] 1(a) and (b) are schematic diagrams illustrating the method of this embodiment. In FIG. 1(a) and (b), the CRISPR / Cas family protein is Cas12a protein as an example.

[0017] First, as shown in Fig. 1(a), when the Cas12a protein 110 and the gRNA 120 are brought into contact with each other, they bind to each other to form a binary complex 130. The gRNA 120 has a base sequence complementary to a target nucleic acid fragment 140 in a part thereof.

[0018] Subsequently, when the target nucleic acid fragment 140 in the sample comes into contact with the binary complex 130, the Cas12a protein 110, the gRNA 120, and the target nucleic acid fragment 140 form a ternary complex 100. At this stage, the Cas12a protein 110 does not express nuclease activity, so the substrate nucleic acid fragment 150 is not cleaved. In the example of Figures 1(a) and (b), the substrate nucleic acid fragment 150 is a single-stranded DNA fragment labeled with a fluorescent substance F and a quenching substance Q. Even if the substrate nucleic acid fragment 150 is irradiated with excitation light, no fluorescence is generated.

[0019] When the ternary complex 100 is formed, the Cas12a protein 110 cleaves the target site of the target nucleic acid fragment 140. In FIG. 1(a), the target site of the target nucleic acid fragment 140 is indicated by an arrowhead. FIG. 1(b) is a schematic diagram showing the ternary complex 100' in which the target site of the target nucleic acid fragment 140 has been cleaved. As shown in FIG. 1(b), the ternary complex 100' expresses nuclease activity. Then, the substrate nucleic acid fragment 150 present around the ternary complex 100' is cleaved. As a result, the fluorescent substance F of the substrate nucleic acid fragment 150 is separated from the quenching substance Q. The fluorescent substance F separated from the quenching substance Q emits fluorescence when irradiated with excitation light.

[0020] Next, the fluorescent substance F is irradiated with excitation light and the fluorescence is detected. If fluorescence is detected, it can be determined that the target nucleic acid fragment 140 is present in the sample.

[0021] In the method of this embodiment, the sample, gRNA 120, CRISPR / Cas family protein 110, and substrate nucleic acid fragment 150 may be mixed and contacted in any order.

[0022] For example, first, the gRNA 120 and the CRISPR / Cas family protein 110 may be contacted to form a binary complex 130 in advance, and then the sample may be contacted. In this case, if a target nucleic acid fragment 140 is present in the sample, the target nucleic acid fragment 140 binds to the binary complex 130 to form a ternary complex 100. Thereafter, the substrate nucleic acid fragment 150 may be contacted.

[0023] Alternatively, after the binary complex 130 is formed, the target nucleic acid fragment 140 and the substrate nucleic acid fragment 150 may be contacted simultaneously.

[0024] Alternatively, the gRNA 120, the CRISPR / Cas family protein 110, and the sample may be contacted simultaneously. Even in this case, if the target nucleic acid fragment 140 is present in the sample, a ternary complex 100 is eventually formed. Thereafter, the substrate nucleic acid fragment 150 may be contacted.

[0025] Alternatively, the sample, the gRNA 120, the CRISPR / Cas family protein 110, and the substrate nucleic acid fragment 150 may be simultaneously contacted. Even in this case, when the target nucleic acid fragment 140 is present in the sample, the ternary complex 100 is finally formed, and when the target site of the target nucleic acid fragment 140 is cleaved in the ternary complex 100, it is converted to the ternary complex 100', which expresses nuclease activity and cleaves the substrate nucleic acid fragment 150.

[0026] (sample) The sample is not particularly limited and can be appropriately selected depending on the purpose. Examples of the sample include biological samples such as saliva, blood, urine, amniotic fluid, malignant ascites, pharyngeal swabs, and nasal swabs, as well as supernatants of cultured cells.

[0027] (Target nucleic acid fragment) Examples of the target nucleic acid fragment in the sample include the above-mentioned cfDNA, ctDNA, microRNA, exosome-derived DNA, etc. For example, a nucleic acid fragment containing a hotspot region of a cancer gene can be used as the target nucleic acid fragment to detect a mutation in the cancer gene contained in the sample.

[0028] When the CRISPR / Cas family protein is a Cas12 protein, a double-stranded DNA fragment can be detected as the target nucleic acid fragment, and when the CRISPR / Cas family protein is a Cas13 protein, a single-stranded RNA fragment or a single-stranded DNA fragment can be detected as the target nucleic acid fragment.

[0029] (gRNA) In the method of this embodiment, the guide RNA (gRNA) is not particularly limited as long as it can be used for the CRISPR / Cas family protein used, and may be a complex of CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA), a single gRNA (sgRNA) that combines tracrRNA and crRNA, or crRNA alone.

[0030] When the CRISPR / Cas family protein used is Cas12a protein, the crRNA can have, for example, the following base sequence. First, the base sequence obtained by removing the protospacer adjacent motif (PAM) sequence from the target base sequence is used as the spacer base sequence. Next, a base sequence in which a scaffold sequence is linked to the 3' end of the spacer base sequence is designed, and its complementary strand is used as the base sequence of the crRNA.

[0031] For example, when the base sequence excluding the PAM sequence from the target base sequence is "5'-GCCAAGCGCACCTAATTTCC-3'" (sequence number 1), the base sequence of the crRNA for the Cas12a protein can be "5'-AAUUUCUACUAAGUGUAGAUGGAAAUUAGGUGCGCUUGGC-3'" (sequence number 2).

[0032] When the CRISPR / Cas family protein used is Cas13a protein, the crRNA can have, for example, the following base sequence: First, a base sequence is designed in which a scaffold sequence is linked to the 3' end of a base sequence complementary to a target base sequence, and the complementary strand is used as the base sequence of the crRNA.

[0033] For example, if the target nucleotide sequence is "5'-AUGGAUUACUUGGUAGAACAGCAAUCUA-3'" (SEQ ID NO: 3), the nucleotide sequence of the crRNA for the Cas13a protein can be "5'-GAUUUAGACUACCCCAAAAACGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU-3'" (SEQ ID NO: 4).

[0034] The target base sequence is a partial base sequence of the base sequence of the target nucleic acid fragment. At least one type of target base sequence is set in one type of target nucleic acid fragment. By setting multiple types of target base sequences in one type of target nucleic acid fragment, a ternary complex of multiple molecules can be formed on one molecule of the target nucleic acid fragment.

[0035] That is, by using multiple types of gRNAs for one type of target nucleic acid fragment, the number of molecules of the ternary complex formed on one molecule of the target nucleic acid fragment can be increased. As a result, it becomes possible to increase the number of molecules of the ternary complex expressing nuclease activity per molecule of the target nucleic acid fragment, and the detection sensitivity of the target nucleic acid fragment can be further increased.

[0036] Therefore, in one embodiment, the present invention provides a method for increasing the detection sensitivity in the above-mentioned method for detecting a target nucleic acid fragment, the method comprising a step of forming a ternary complex of multiple molecules on one molecule of a target nucleic acid fragment by using multiple types of gRNA.

[0037] (CRISPR / Cas family proteins) In the method of this embodiment, the CRISPR / Cas family protein can be any protein that expresses nuclease activity after forming a ternary complex with the gRNA and the target nucleic acid fragment. As described above, more precisely, the nuclease activity is expressed after the ternary complex is formed and the CRISPR / Cas family protein cleaves the target nucleic acid fragment.

[0038] Such CRISPR / Cas family proteins include Cas12 protein, Cas13 protein, etc. In the present specification, Cas12 protein and Cas13 protein may be Cas12 protein, Cas13 protein, orthologs of these proteins, modified forms of these proteins, etc.

[0039] More specific examples of CRISPR / Cas family proteins that can be used in the method of this embodiment include the Cas12a protein derived from Lachnospiraceae bacterium ND2006 (LbCas12a, UniProtKB accession number: A0A182DWE3), the Cas12a protein derived from Acidaminococcus sp. (AsCas12a, UniProtKB accession number: U2UMQ6), the Cas12a protein derived from Francisella tularensis subsp. novicida (FnCas12a, UniProtKB accession number: A0Q7Q2), the Cas12b protein derived from Alicyclobacillus acidoterrestris (AaCas12b, UniProtKB accession number: T0D7A2), and the Cas12b protein derived from Leptotrichia Cas13a protein from Lachnospiraceae bacterium NK4A179 (LbaCas13a, NCBI accession number: WP_022785443.1), Cas13a protein from Leptotrichia buccalis C-1013-b (LbuCas13a, NCBI accession number: WP_015770004.1), Cas13b protein from Bergeyella zoohelcum (BzoCas13b, NCBI accession number: WP_002664492), Cas13b protein from Prevotella intermedia (PinCas13b, NCBI accession number: WP_036860899), and Cas13b protein from Prevotella buccae (PbuCas13b, NCBI accession number: WP_004343973), Alistipes sp. ZOR0009 (AspCas13b, NCBI accession number: WP_047447901), Prevotella sp.The Cas13b protein derived from MA2016 (PsmCas13b, NCBI accession number: WP_036929175), the Cas13b protein derived from Riemerella anatipestifer (RanCas13b, NCBI accession number: WP_004919755), the Cas13b protein derived from Prevotella aurantiaca (PauCas13b, NCBI accession number: WP_025000926), the Cas13b protein derived from Prevotella saccharolytica (PsaCas13b, NCBI accession number: WP_051522484), the Cas13b protein derived from Prevotella intermedia (Pin2Cas13b, NCBI accession number: WP_061868553), and the Cas13b protein derived from Capnocytophaga canimorsus (CcaCas13b, NCBI accession number: WP_013997271), Porphyromonas gulae (PguCas13b, NCBI accession number: WP_039434803), Prevotella sp. P5-125 (PspCas13b, NCBI accession number: WP_044065294), Porphyromonas gingivalis (PigCas13b, NCBI accession number: WP_053444417), Prevotella intermedia (Pin3Cas13b, NCBI accession number: WP_050955369), Enterococcus Examples of Csm6 proteins include the Csm6 protein derived from Lactobacillus italicus (EiCsm6, NCBI accession number: WP_007208953.1), the Csm6 protein derived from Lactobacillus salivarius (LsCsm6, NCBI accession number: WP_081509150.1), and the Csm6 protein derived from Thermus thermophilus (TtCsm6, NCBI accession number: WP_011229148.1).

[0040] In the method of this embodiment, the CRISPR / Cas family protein may be a mutant of the above-mentioned Cas family protein. For example, a mutant having increased nuclease activity after forming a ternary complex can be used as the mutant.

[0041] (Substrate nucleic acid fragment) The substrate nucleic acid fragment is labeled with a fluorescent substance and a quencher, and when cleaved by the nuclease activity of the ternary complex and the fluorescent substance is separated from the quencher, it emits fluorescence when irradiated with excitation light.

[0042] The substrate nucleic acid fragment may be appropriately selected depending on the substrate specificity of the CRISPR / Cas family protein to be used. For example, Cas12 protein cleaves single-stranded DNA as a substrate. Therefore, when using Cas12 protein, it is advisable to use single-stranded DNA as the substrate nucleic acid fragment. Moreover, Cas13 protein cleaves single-stranded RNA as a substrate. Therefore, when using Cas13 protein, it is advisable to use single-stranded RNA as the substrate nucleic acid fragment.

[0043] The combination of the fluorescent substance and the quenching substance is such that the fluorescence of the fluorescent substance can be quenched when the two substances are placed close to each other. For example, when FAM, HEX, etc. are used as the fluorescent substance, Iowa Black FQ (IDT), TAMRA, etc. can be used as the quenching substance.

[0044] It is known that the type of Cas13 protein has specificity in the base sequence of the single-stranded RNA to be cleaved. Specifically, for example, it has been reported that the LwaCas13a protein, the CcaCas13b protein, the LbaCas13a protein, and the PsmCas13b protein recognize and cleave the base sequences AU, UC, AC, and GA in the substrate nucleic acid fragment, respectively.

[0045] Therefore, in the method of this embodiment, for example, LwaCas13a protein, CcaCas13b protein, LbaCas13a protein, and PsmCas13b protein are used as CRISPR / Cas family proteins, different gRNAs are bound to each CRISPR / Cas family protein as gRNA, single-stranded RNA containing the base sequences AU, UC, AC, and GA are used as substrate nucleic acid fragments, and each substrate nucleic acid fragment is labeled with a different fluorescent dye that can be distinguished from each other, thereby detecting four types of target nucleic acid fragments in one reaction space. That is, multicolor detection can be performed.

[0046] (Reaction Space) As a method for detecting target substances with high accuracy, a technology for performing enzyme reactions in many tiny reaction spaces is being considered. These methods are called digital measurement. In digital measurement, the sample is divided into an extremely large number of tiny reaction spaces to detect signals.

[0047] The signal from each reaction space is then binarized, and the presence or absence of the target substance is determined, and the number of molecules of the target substance is measured. Digital measurement can significantly improve detection sensitivity and quantitativeness compared to conventional ELISA, real-time PCR, and other methods.

[0048] The method of this embodiment is performed by digital measurement. More specifically, the contact of the sample, the CRISPR / Cas family protein, the gRNA, and the substrate nucleic acid fragment is performed by dividing the reaction space into small reaction spaces. The volume of each reaction space is 10aL to 100pL, and may be, for example, 10aL to 10pL, or may be, for example, 10aL to 1pL, or may be, for example, 10aL to 100fL, or may be, for example, 10aL to 10fL. By having the reaction space in the above range, it becomes possible to detect the presence of the target nucleic acid fragment with high sensitivity without amplifying the target nucleic acid fragment.

[0049] By carrying out the method of this embodiment under the condition that 0 or 1 target nucleic acid fragment is introduced per reaction space, digital measurement can be performed. In other words, the number of reaction spaces where a signal is detected can be made to correspond to the number of target nucleic acid fragment molecules in the sample.

[0050] The reaction space may be, for example, a droplet. Alternatively, the reaction space may be a well formed on a substrate. Fig. 2(a) is a top view showing an example of a fluidic device including a substrate on the surface of which wells, each of which has a volume of 10 aL to 100 pL, are formed. Fig. 2(b) is a cross-sectional view taken along line bb' in Fig. 2(a).

[0051] 2(a) and (b), the fluidic device 200 includes a substrate 210 having wells 211 with a volume of 10 aL to 100 pL formed on its surface, a spacer 220, and a cover member 230 having a liquid inlet 231 formed therein. A plurality of wells 211 are present, forming a well array 212. The space between the substrate 210 and the cover member 230 functions as a flow path for flowing a sample, gRNA, a CRISPR / Cas family protein, a substrate nucleic acid fragment, and the like.

[0052] The shape of the well is not particularly limited as long as the volume is within the above-mentioned range, and may be, for example, a cylinder or a polyhedron formed by multiple faces (for example, a rectangular parallelepiped, a hexagonal prism, an octagonal prism, etc.).

[0053] In the fluidic device 200, a plurality of wells 211 of the same shape and size form a well array 212. The same shape and size means that the wells have the same shape and the same capacity to the extent required for digital measurement, and variations in the order of manufacturing error are permissible.

[0054] 3(a) to (c) are schematic cross-sectional views for explaining an example of a procedure for carrying out the method of this embodiment using the fluidic device 200. First, a sample, gRNA, and a CRISPR / Cas family protein are mixed to form a ternary complex. Next, the ternary complex and a substrate nucleic acid fragment are mixed to prepare an assay solution 310, which is immediately introduced from the liquid inlet 231 of the fluidic device 200. As a result, as shown in FIG. 3(a), the inside of the well 211 and the space between the substrate 210 and the cover member 230 are filled with the assay solution 310.

[0055] Next, as shown in FIG. 3(b), a sealant 320 is introduced from the liquid inlet 231. In the example of FIG. 3(b), an organic solvent containing lipids 321 is used as the sealant 320. As the lipids 321, natural lipids derived from soybeans, E. coli, etc., or artificial lipids such as dioleoylphosphatidylethanolamine (DOPE) and dioleoylphosphatidylglycerol (DOPG) can be used. As the organic solvent, hexadecane or chloroform can be used. When the sealant 320 is introduced, the opening of the well 211 is sealed by the first lipid membrane 322 with the inside of the well 211 filled with the assay solution 310. The hydrophilic group of each lipid 321 constituting the first lipid membrane 322 faces the well 211 side. As a result, each well 211 becomes an independent reaction space. In this state, the well array 212 may be irradiated with excitation light to measure fluorescence.

[0056] Also, a lipid bilayer membrane can be formed by further stacking a lipid membrane on the first lipid membrane 322. In this case, as shown in FIG. 3(c), a membrane-forming aqueous solution 330 for forming a lipid bilayer membrane 324 is introduced from a liquid inlet 231. The composition of the membrane-forming aqueous solution 330 can be, for example, a 10 mM pH buffer solution (pH 5-9) or a 10 mM sodium chloride aqueous solution. When the membrane-forming aqueous solution 330 is introduced, a second lipid membrane 323 is stacked on the first lipid membrane 322, forming a lipid bilayer membrane 324. As a result, each well 211 becomes an independent reaction space. In this state, the well array 212 may be irradiated with excitation light to measure fluorescence.

[0057] When the opening of the well 211 is sealed with a lipid bilayer membrane 324, the lipid vesicles can be fused to the lipid bilayer membrane 324. For example, by fusing exosomes to the lipid bilayer membrane 324, the contents of the exosomes can be released into the inside of the well 211.

[0058] Therefore, for example, first, gRNA, a CRISPR / Cas family protein, and a substrate nucleic acid fragment are encapsulated in well 211, and the opening of well 211 is sealed with a lipid bilayer membrane 324, and then exosomes are brought into contact with lipid bilayer membrane 324 as a sample.

[0059] As a result, the exosome fuses with the lipid bilayer 324, and the contents of the exosome are released into the well 211. If the contents of the exosome contain a target nucleic acid fragment, a ternary complex is formed inside the well 211, the substrate nucleic acid fragment is cleaved, and fluorescence is detected by irradiation with excitation light.

[0060] As shown in FIG. 4(a), in the method of this embodiment, a CRISPR / Cas family protein 110 may be immobilized in advance on the inner surface of a well 211. Here, as shown in FIG. 4(b), the CRISPR / Cas family protein 110 may bind to a gRNA 120 to form a binary complex 130. As a result, it is possible to increase the possibility that a ternary complex 100 is present inside the well 211 when the sample is contacted, and it is possible to dramatically improve the detection sensitivity.

[0061] Methods for immobilizing the CRISPR / Cas family protein on the inner surface of the well 211 include physical adsorption, covalent bonding between a functional group present on the inner surface of the well 211 and a functional group present on the surface of the CRISPR / Cas family protein using a chemical linker, and the like. Examples of the functional group include a hydroxyl group, an amino group, and a thiol group. Alternatively, the CRISPR / Cas family protein may be immobilized on the inner surface of the well 211 by using, for example, a click reaction using an azide group and an alkyne group.

[0062] [Target nucleic acid fragment detection kit] In one embodiment, the present invention provides a kit for detecting a target nucleic acid fragment, the kit comprising a substrate having a well with a volume of 10 aL to 100 pL formed on the surface thereof, a gRNA complementary to a target nucleic acid fragment, a CRISPR / Cas family protein, and a substrate nucleic acid fragment, the CRISPR / Cas family protein expressing nuclease activity after forming a ternary complex with the gRNA and the target nucleic acid fragment, the substrate nucleic acid fragment being labeled with a fluorescent substance and a quencher, and emitting fluorescence when cleaved by the nuclease activity of the ternary complex and the fluorescent substance separated from the quencher by irradiation with excitation light. By using the kit of this embodiment, the above-mentioned method for detecting a target nucleic acid fragment can be suitably carried out.

[0063] In the kit of this embodiment, the substrate having wells with a volume of 10 aL to 100 pL formed on its surface, the target nucleic acid fragment, the gRNA, the CRISPR / Cas family protein, and the substrate nucleic acid fragment are the same as those described above.

[0064] In the kit of this embodiment, the CRISPR / Cas family protein may be a Cas12 protein or a Cas13 protein. Specific examples of the Cas12 protein or the Cas13 protein are the same as those described above.

[0065] As shown in FIG. 4(a), in the kit of this embodiment, the CRISPR / Cas family protein 110 may be immobilized on the inner surface of a well 211. Here, as shown in FIG. 4(b), the CRISPR / Cas family protein 110 may bind to a gRNA 120 to form a binary complex 130. As a result, it is possible to increase the possibility that the ternary complex 100 is present inside the well 211 when the sample is contacted, and it is possible to dramatically improve the detection sensitivity.

[0066] The method for immobilizing the CRISPR / Cas family protein on the inner surface of the well is similar to that described above.

[0067] 4(c), in the kit of this embodiment, the gRNA 120 may be immobilized on the inner surface of the well 211. Here, an additional sequence functioning as a linker may be added to the gRNA 120.

[0068] As a result, as shown in FIG. 4(d), when the CRISPR / Cas family protein 110 is introduced into the well 211, the CRISPR / Cas family protein 110 binds to the gRNA 120 to form a binary complex 130, which is immobilized on the inner surface of the well 211.

[0069] Wells immobilized with gRNA may be easier to store than wells immobilized with protein. EXAMPLES

[0070] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.

[0071] Materials and Methods (Preparation of Cas12a protein) The expression vector of Lachnospiraceae bacterium ND2006 Cas12a (LbCas12a) was transfected into Escherichia coli BL21 (DE3) strain to express it. The expression vector was a pET-based vector with a 10xHis tag, maltose binding protein (MBP), and a TEV protease cleavage site at the N-terminus. The expressed Cas12a protein was purified using Ni-NTA resin. Then, after reacting with TEV protease at 4°C overnight, cation exchange chromatography was performed using an MBPTrap HP column (GE Healthcare) and a HiTrap Heparin HP column (GE Healthcare) connected thereto, and further purification was performed by gel filtration chromatography using a Superdex 200 column (GE Healthcare).

[0072] (Preparation of Cas13a protein) The expression vector of Leptotrichia wadei Cas13a (LwCas13a) was transfected into Escherichia coli BL21 (DE3) strain to express it. The expression vector was a pET-based vector with a 10xHis tag, maltose binding protein (MBP), and a TEV protease cleavage site at the N-terminus. The expressed Cas13a protein was purified using Ni-NTA resin. Then, after reacting with TEV protease overnight at 4°C, cation exchange chromatography was performed using an MBPTrap HP column (GE Healthcare) and a HiTrap Heparin HP column (GE Healthcare) connected thereto, and further purification was performed by gel filtration chromatography using a Superdex 200 column (GE Healthcare).

[0073] (Preparation of target nucleic acid fragment) The target nucleic acid fragment (double-stranded DNA fragment) was prepared by annealing a single-stranded DNA fragment (SEQ ID NO: 5) and a complementary single-stranded DNA fragment, each of which was chemically synthesized by an outside contractor (IDT). The target nucleic acid fragment (single-stranded RNA fragment, SEQ ID NO: 6) was chemically synthesized by an outside contractor (IDT).

[0074] (Preparation of gRNA) A DNA fragment encoding gRNA (crRNA) was prepared by PCR amplification using overlapping primers containing a T7 promoter sequence, a 20-base target sequence, and a scaffold sequence as a template. The resulting DNA fragment was then subjected to an in vitro transcription reaction to prepare crRNA. The base sequence of gRNA (crRNA) for Cas12a protein is shown in SEQ ID NO: 2, and the base sequence of gRNA (crRNA) for Cas13a protein is shown in SEQ ID NO: 4.

[0075] (Preparation of Substrate Nucleic Acid Fragment) The substrate nucleic acid fragment (single-stranded DNA fragment) was chemically synthesized by an outside contractor (IDT). The 5' end of the substrate nucleic acid fragment was labeled with the fluorescent substance FAM, and the 3' end was labeled with the quenching substance Iowa Black FQ (IDT). The base sequence of the chemically synthesized substrate nucleic acid fragment (single-stranded DNA fragment) was "5'-(FAM)TTATT(IABkFQ)-3'" (where "IABkFQ" stands for Iowa Black FQ).

[0076] The substrate nucleic acid fragment (single-stranded RNA fragment) was chemically synthesized by an outside contractor (IDT). The 5' end of the substrate nucleic acid fragment was labeled with the fluorescent substance FAM, and the 3' end was labeled with the quenching substance Iowa Black FQ (IDT). The base sequence of the chemically synthesized substrate nucleic acid fragment (single-stranded RNA fragment) was "5'-(FAM)UUUUU(IABkFQ)-3'" (where "IABkFQ" stands for Iowa Black FQ).

[0077] (Preparation of Well Array) 5(a) to (f) are schematic cross-sectional views illustrating each step of forming a well array. First, as shown in Fig. 5(a), glass substrate 210 was immersed in a 10 M potassium hydroxide solution for about 24 hours to form hydroxyl groups on the surface.

[0078] 5(b), a fluororesin (CYTOP, manufactured by AGC Corporation) was spin-coated on the surface of the glass substrate 210 to form a film 520. The spin-coating conditions were 2000 rps (revolutions per second) for 30 seconds. Under these conditions, the film 520 had a thickness of about 500 nm.

[0079] Subsequently, the film 520 was adhered to the surface of the glass substrate 510 by baking on a hot plate at 180° C. for 1 hour to cause dehydration condensation between the silanol groups of the film 520 (CYTOP) and the hydroxyl groups on the glass surface.

[0080] Subsequently, as shown in FIG. 5( c ), a resist (AZ-4903, manufactured by AZ Electronic Materials) was spin-coated on the surface of the film 520 at 4000 rps for 60 seconds to form a resist film 530 .

[0081] Subsequently, the glass substrate 210 was baked on a hot plate at 110° C. for 1 hour to evaporate the organic solvent in the resist film 530 , thereby adhering the resist film 530 to the surface of the film 520 .

[0082] Next, as shown in FIG. 5(d), using a mask with a well array pattern, the resist film 530 was exposed to ultraviolet light at 250 W for 7 seconds using an exposure machine (manufactured by SAN-EI). The resist film 530 was then developed by immersing it in a developer (AZ developer, manufactured by AZ Electronic Materials) for 5 minutes. As a result, the resist film 530 in the portion where the wells were to be formed was removed.

[0083] Next, as shown in FIG. 5(e), the film 520 masked with the resist film 530 was dry-etched for 30 minutes using a reactive ion etching device (manufactured by Samco) under conditions of O2 50 sccm, pressure 10 Pa, and output 50 W, thereby forming a well 211 in the film 520.

[0084] 5(f), the glass substrate 210 was immersed in acetone, washed with isopropanol, and then washed with pure water to remove the resist film 530 and obtain an array of wells 211. The well array 212 was formed by forming cylindrical wells 211 with a diameter of 4 μm and a depth of 500 nm over an area of ​​1 cm. 2 The well array 212 had a volume of 6 fL per well.

[0085] (Fabrication of fluidic devices) 2(a) and (b), a fluidic device was fabricated by placing a spacer 220 on a substrate 210 having wells 211 formed on its surface as described above, and then placing a glass plate 230 having a liquid inlet 231 formed thereon. As a result, a fluidic device 200 was formed in which the space between the well array 212 and the glass plate 230 served as a flow path.

[0086] [Experimental Example 1] (Study on concentration dependency of ternary complex) The above-mentioned Cas12a protein, gRNA (SEQ ID NO: 2) and target nucleic acid fragment were mixed with buffer A having the composition shown in Table 1 below so that the final concentration of Cas12a protein was 200 nM, the final concentration of gRNA was 250 nM, and the final concentration of target nucleic acid fragment was 200 nM, and the mixture was left to stand at 37°C for 30 minutes to form a ternary complex. Hereinafter, this solution is referred to as a ternary complex solution.

[0087] [Table 1]

[0088] In addition, a solution was prepared by dissolving the substrate nucleic acid fragment in buffer B having the composition shown in Table 2 below to a final concentration of 5 μM.

[0089] [Table 2]

[0090] Five of the above-mentioned fluidic devices were prepared. Next, the above-mentioned ternary complex solution and the solution of the substrate nucleic acid fragment were mixed to prepare assay solutions with final concentrations of the ternary complex of 266 pM, 133 pM, 67 pM, 34 pM, and 17 pM, respectively, and these were immediately introduced from the liquid inlet of each fluidic device. As a result, each assay solution was introduced into each well of each well array.

[0091] Next, a sealant ("FC-40", Sigma) was introduced into each fluidic device through the liquid inlet. As a result, the wells into which the assay solution had been introduced were sealed with the sealant, and each well became an independent reaction space. After a few minutes, the well arrays of each fluidic device were observed under a fluorescent microscope.

[0092] Figure 6(a) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the ternary complex is 17 pM. Figure 6(b) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the ternary complex is 67 pM. Figure 6(c) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the ternary complex is 133 pM. Figure 6(d) is a graph showing the results of calculating the percentage of wells in which fluorescence was detected based on photographs of the well array into which each assay solution was introduced.

[0093] As a result, it was revealed that the percentage of wells in which fluorescence was detected increased in a concentration-dependent manner of the ternary complex.

[0094] [Experimental Example 2] (Study on concentration dependency of target nucleic acid fragment) The above-mentioned Cas12a protein, gRNA (SEQ ID NO: 2) and target nucleic acid fragment were mixed with the buffer A having the composition shown in Table 1 above so that the final concentration of Cas12a protein was 200 nM, the final concentration of gRNA was 250 nM, and the final concentrations of the target nucleic acid fragment were 4000 pM, 400 pM, 40 pM, 4 pM, and 0.4 pM, respectively, and the mixture was left to stand at 37 ° C. for 30 minutes to form a ternary complex. Hereinafter, this solution is referred to as a ternary complex solution.

[0095] Five of the above-mentioned fluidic devices were prepared. In addition, a solution was prepared by dissolving the substrate nucleic acid fragment in buffer B having the composition shown in Table 2 above to a final concentration of 5 μM.

[0096] Next, the above-mentioned ternary complex solution and the solution of the substrate nucleic acid fragment were mixed to prepare assay solutions, which were then immediately introduced into the liquid inlets of each fluidic device, resulting in the assay solutions being introduced into each well of the well array.

[0097] Next, a sealant ("FC-40", Sigma) was introduced into each fluidic device through the liquid inlet. As a result, the wells into which the assay solution had been introduced were sealed with the sealant, and each well became an independent reaction space. After a few minutes, the well arrays of each fluidic device were observed under a fluorescent microscope.

[0098] Figure 7(a) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 4 pM. Figure 7(b) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 40 pM. Figure 7(c) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 400 pM. Figure 7(d) is a graph showing the results of calculating the percentage of wells in which fluorescence was detected based on photographs of the well array into which each assay solution was introduced.

[0099] As a result, it was revealed that the percentage of wells in which fluorescence was detected increased depending on the concentration of the target nucleic acid fragment.

[0100] [Experimental Example 3] (Study using Cas13a 1) The above-mentioned Cas13a protein, gRNA (sequence number 4) and target nucleic acid fragment were mixed with buffer A having the composition shown in Table 1 above so that the final concentration of Cas13a protein was 200 nM, the final concentration of gRNA was 250 nM and the final concentration of the target nucleic acid fragment was 200 nM, and the mixture was allowed to stand at 37°C for 30 minutes to form a ternary complex.

[0101] Furthermore, solutions were prepared by dissolving the substrate nucleic acid fragment in buffer B having the composition shown in Table 2 above to give final concentrations of 2, 5, and 10 μM.

[0102] Four of the above-mentioned fluidic devices were prepared. Next, the above-mentioned ternary complex solution and the solution of the substrate nucleic acid fragment were mixed to prepare assay solutions in which the final concentration of the ternary complex was 30 pM and the final concentration of the substrate nucleic acid fragment was 2, 5, and 10 μM, respectively, and these were immediately introduced from the liquid inlet of each fluidic device. For comparison, an assay solution not containing the target nucleic acid fragment was also prepared and introduced from the liquid inlet of the fluidic device. As a result, each assay solution was introduced into each well of each well array.

[0103] Next, a sealant ("Hexadecane", Sigma) was introduced into each fluidic device through the liquid inlet. As a result, the wells into which the assay solution had been introduced were sealed with the sealant, and each well became an independent reaction space. Next, the well arrays of each fluidic device were observed over time using a fluorescent microscope.

[0104] Figure 8(a) is a graph summarizing the change in fluorescence intensity over time for wells in which fluorescence was detected for each assay solution. The horizontal axis is time (seconds) and the vertical axis is fluorescence intensity. In Figure 8(a), "w / o tgRNA" indicates the results for assay solutions that do not contain target nucleic acid fragments, "w / tgRNA" indicates the results for assay solutions that contain target nucleic acid fragments, and "FAM-Q" indicates the substrate nucleic acid fragments. The results revealed that the increase in fluorescence intensity was saturated in approximately 2 minutes.

[0105] Figure 8(b) is a graph showing the relationship between the concentration of the substrate nucleic acid fragment and the rate of increase in fluorescence intensity based on Figure 8(a). The horizontal axis shows the concentration of the substrate nucleic acid fragment (μM), and the vertical axis shows the rate of increase in fluorescence intensity (ΔI / s). As a result, it was revealed that the rate of increase in fluorescence intensity is proportional to the concentration of the substrate nucleic acid fragment.

[0106] [Experimental Example 4] (Study using Cas13a 2) The above-mentioned Cas13a protein, gRNA (SEQ ID NO: 4) and target nucleic acid fragment were mixed in buffer A having the composition shown in Table 1 above so that the final concentration of Cas13a protein was 200 nM, the final concentration of gRNA was 250 nM, and the final concentrations of the target nucleic acid fragment were 30 pM, 3 pM, 0.3 pM, and 0 pM, respectively, and the mixture was left to stand at 37°C for 30 minutes to form a ternary complex. Hereinafter, this solution is referred to as a ternary complex solution.

[0107] Four of the above-mentioned fluidic devices were prepared. In addition, a solution was prepared by dissolving the substrate nucleic acid fragment in buffer B having the composition shown in Table 2 above to a final concentration of 5 μM.

[0108] Next, the above-mentioned ternary complex solution and the solution of the substrate nucleic acid fragment were mixed to prepare assay solutions, which were then immediately introduced into the liquid inlets of each fluidic device, resulting in the assay solutions being introduced into each well of the well array.

[0109] Next, a sealant ("Hexadecane", Sigma) was introduced into each fluidic device through the liquid inlet. As a result, the wells into which the assay solution had been introduced were sealed with the sealant, and each well became an independent reaction space. After a few minutes, the well arrays of each fluidic device were observed under a fluorescent microscope.

[0110] FIG. 9(a) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 0 pM. FIG. 9(b) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 0.3 pM. FIG. 9(c) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 3 pM. Also, FIG. 9(d) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 30 pM. The scale bar is 50 μm.

[0111] Figure 10(a) is a representative graph showing the number of wells that showed a given fluorescence intensity (relative value) based on a photograph of a well array into which each assay solution was introduced. Figure 10(b) is a graph similar to Figure 10(a) for assay solutions with final concentrations of the target nucleic acid fragment of 30 pM, 3 pM, 0.3 pM, and 0 pM, respectively, enlarging the area corresponding to the area surrounded by the dotted line in Figure 10(a).

[0112] As a result, it was revealed that the percentage of wells in which fluorescence was detected increased depending on the concentration of the target nucleic acid fragment.

[0113] FIG. 11 is a graph showing the relationship between the number of wells in which fluorescence was detected and the final concentration of the target nucleic acid fragment. The vertical axis shows the number of wells in which fluorescence was detected, and the horizontal axis shows the final concentration of the target nucleic acid fragment. In FIG. 11, the solid circle shows the result of using a fluidic device, and the dashed circle shows the result of a similar experiment performed using a plate reader. The graph in the upper left of FIG. 11 shows an enlarged view. In the experiment using a plate reader, a 384-well plate was used instead of the fluidic device. As a result, it was found that the detection sensitivity when using the fluidic device was 56 fM. [Industrial Applicability]

[0114] According to the present invention, a technique can be provided that enables highly sensitive detection of a target nucleic acid fragment without amplification.

Claims

1. A method for detecting a target nucleic acid fragment in a sample, comprising the steps of: Contacting the sample with a gRNA complementary to the target nucleic acid fragment, a CRISPR / Cas family protein, and a substrate nucleic acid fragment, The CRISPR / Cas family protein expresses nuclease activity after forming a ternary complex with the gRNA and the target nucleic acid fragment, the substrate nucleic acid fragment is labeled with a fluorescent substance and a quencher, and when the substrate nucleic acid fragment is cleaved by the nuclease activity of the ternary complex and the fluorescent substance is separated from the quencher, the substrate nucleic acid fragment emits fluorescence upon irradiation with excitation light; the contact is carried out in a reaction space having a volume of 10 aL to 100 pL, so that when the target nucleic acid fragment is present in the sample, the ternary complex is formed, the substrate nucleic acid fragment is cleaved, and the fluorescent substance is separated from the quenching substance; irradiating the fluorescent material with the excitation light and detecting the fluorescence; wherein detection of the fluorescence indicates the presence of the target nucleic acid fragment in the sample; The method, wherein the CRISPR / Cas family protein is a Cas12 protein or a Cas13 protein.

2. The method according to claim 1 , wherein 0 or 1 target nucleic acid fragment is introduced per reaction space.

3. The method according to claim 1 or 2, wherein the reaction space is a well formed on a substrate.

4. The method of claim 3, wherein the CRISPR / Cas family protein is immobilized on an inner surface of the well.

5. A substrate having a well having a volume of 10 aL to 100 pL formed on its surface; a gRNA complementary to a target nucleic acid fragment; A CRISPR / Cas family protein; a substrate nucleic acid fragment, The CRISPR / Cas family protein expresses nuclease activity after forming a ternary complex with the gRNA and the target nucleic acid fragment, the substrate nucleic acid fragment is labeled with a fluorescent substance and a quencher, and when the substrate nucleic acid fragment is cleaved by the nuclease activity of the ternary complex and the fluorescent substance is separated from the quencher, the substrate nucleic acid fragment emits fluorescence upon irradiation with excitation light; The CRISPR / Cas family protein is a Cas12 protein or a Cas13 protein; A kit for detecting the target nucleic acid fragment.

6. The kit of claim 5 , wherein the CRISPR / Cas family protein is immobilized on an inner surface of the well.

7. The kit of claim 5 or 6, wherein the gRNA is immobilized on an inner surface of the well.

Citation Information

Patent Citations

  • Methods and compositions for detecting a target RNA

    US20170362644A1

  • Biomolecule analysis kit and biomolecule analysis method

    WO2015115635A1

  • Target molecule detection method

    WO2019098301A1

  • Type v crispr / CAS effector proteins for cleaving ssdnas and detecting target dnas

    WO2019104058A1

Cited By

  • Method and kit for detecting target nucleic acid fragment

    JPWO2022145354A1